Glucocorticoids Clinical Trial
Official title:
Treatment Of Giant Cell Arteritis Patients With Ultra-short Glucocorticosteroids And tociliZumab: Role of Imaging in a Observational Study
The objective of our study is to evaluate the functional and morphological imaging variations at 24 and 52 weeks compared to baseline during TCZ-treatment and 6 months after the suspension of TCZ. We will also evaluate the variations of aortic dilatation during the study period using the PET/CT in comparison with an hystorical cohort of patients with LVV treated with GCs only and longitudinally followed at our rheumatology division.
1. Trial Design Monocentric observational study, single arm, based on imaging of patients with active Large Vessel Giant Cell Arteritis (LV-GCA) , treated with Tocilizumab (TCZ) s.c. and with ultra-short glucocorticosteroids (GCs). 2. Duration of study per Subject 52 weeks of observation during standard of care (SOC) and 24 weeks of follow-up 3. Target Population Patients aged older than 50 years with active large vessel giant cell arteritis (LV-GCA) based on evidence of large vasculitis at imaging. Patients with active disease will be enrolled according to the following inclusion criteria: - PET/CT showing vascular FDG uptake ≥2 in at least one vascular district and at least one among - ESR >40 mm/h or CRP >10 mg/l - Cranial or systemic symptoms of GCA or symptoms of polymyalgia rheumatica (PMR) 4. Primary Objectives - To evaluate the functional and morphological imaging (PET and MRA scores) variations at 24, 52 and 76 weeks compared to baseline values. - To evaluate the proportion of patients with relapse free remission (RFR) at week 24, 52 and 76. - To assess agreement between of MRA and PET scores and physician-determined disease activity status. 5. Secondary Objectives - To evaluate if patients have a reduced risk of aortic dilatation compared with an hystorical cohort of patients with LVV treated with GCs only and longitudinally followed at our rheumatology division. - immunological effects of steroid and TCZ at baseline, after 3 days, at week 24, 52 and 76 ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03007186 -
Glucose Monitoring During Threatening Preterm Birth in Patients With and Without Gestational Diabetes Mellitus
|
||
Not yet recruiting |
NCT05598411 -
CST1-Guided Oral Glucocorticoids Management for CRSwNP
|
Phase 4 | |
Recruiting |
NCT05522465 -
Short-course High-dose Prednisone and Dexamethasone in Children With ITP
|
Phase 4 | |
Recruiting |
NCT05598424 -
CST1 Predictive Model of Oral Glucocorticoid Therapy Sensitivity for Chronic Rhinosinusitis With Polyps
|
Phase 4 | |
Completed |
NCT03125941 -
High vs Low Dose Dexamethasone on Complications in the Immediate Postoperative Phase After Mastectomy
|
Phase 4 | |
Not yet recruiting |
NCT03804723 -
Glucocorticoids Withdrawal in Early Systemic Lupus Erythematosus
|
N/A | |
Recruiting |
NCT04094298 -
Use of Extended Release Triamcinolone in the Treatment of Rotator Cuff Disease
|
Phase 3 | |
Recruiting |
NCT04574232 -
SporTRIA Study: A Multicentre Trial for Excretion Kinetics of Triamcinolone Acetonide Following Sport Related Intra-articular Injections in Knees; Definitions of the Washout Periods
|
N/A | |
Completed |
NCT02857842 -
Corticosteroid Reduction in COPD
|
Phase 4 | |
Enrolling by invitation |
NCT05506033 -
Optimization of Glucocorticoid Taper Strategies for SLE-ITP
|
N/A |